Newsletter | January 27, 2022

01.27.22 -- 2021's Bioprocessing Year In Review

Featured Editorial
Industry Insights
Is Your Biologic At Risk For Protein Aggregation? Part 3

The main culprit of a failing biologic drug is usually a flawed formulation. In this article, we cover formulation components and how they may affect protein aggregation. Part three of a three-part series.

Top Four Considerations For Tech Transfer Performance

Successful tech transfer is how long-term strategic CDMO relationships begin. A product’s continued success may hinge on this critical exchange of product data and required regulatory filings.

Learn About Affinity Chromatography Using Tagged Protein Purification

Affinity tags can help you simplify your protein purification and protect your outcomes. Choosing the right tag is essential to get the purity, solubility, and protein quality your application needs. With our handbook you can learn how to prepare a recombinant protein in the quantity and quality you need.

Guide Clients Through Drug Development With Intelligent Collaboration

This article recounts a recent discussion with the general manager of Pfizer CentreOne, regarding what it’s like to lead an embedded CDMO within one of the largest pharmaceutical companies.

Process Impurities: Don’t Let PEI Or HCP Derail Your Biotherapy

Learn product characterization strategies to de-risk manufacturing and detect and characterize host cell proteins (HCPs) and polyethylenimine (PEI) in monoclonal antibody (mAb) and cell and gene therapies.

News Headlines
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.